Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01970930 · ClinicalTrials.gov registry record

Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients

A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
131
Enrollment target

NCT01970930 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 131 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01970930 has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
131 participants
Enrollment target

Study Summary

The purpose of the study is to isolate and characterize stem cells of patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) to find out why these cells are not working the way they should be and why they seem to be sensitive to regulatory factors in the blood, such as clotting.

Interventions

  • PROCEDURE Blood specimen

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2012-08
Est. Completion 2016-06-02

What the Registry Record Tells You About NCT01970930

The ClinicalTrials.gov registry entry for NCT01970930 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Blood specimen is the first listed.

NCT01970930 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01970930 about?

NCT01970930 is a clinical study titled "Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients". The purpose of the study is to isolate and characterize stem cells of patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) to find out why these cells are not working the way they should be and why they seem to be sensitive to regulatory factors in the blood, such as clotting.

What is the current status of trial NCT01970930?

This trial is currently completed. The enrollment target is 131 participants. The study started on 2012-08. Estimated completion is 2016-06-02.

What interventions are being tested in trial NCT01970930?

The interventions under investigation include: Blood specimen (PROCEDURE).

Who is sponsoring clinical trial NCT01970930?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.